IE 11 is a very old browser and is not supported on this site.

Security of supply and procurement

GRI report

Supply bottlenecks in the pharmaceutical supply chain are increasing worldwide, including in Switzerland. Galenica strives to ensure the highest possible availability of medicines in order to guarantee a reliable supply to the population.


Management of the material topic (GRI 3-3)

Causes of the increasing supply bottlenecks include centralised manufacturing at just a few locations in the world as well as outages and quality problems in the value chain. As a leading fully integrated healthcare provider, Galenica depends on the ability of manufacturers to deliver. As a result, the reliable procurement and supply of medicines to the population are becoming increasingly important for Galenica. The challenges posed by the COVID-19 pandemic have further reinforced the relevance of procurement and supply security. A reliable supply of medicines is crucial to the health and well-being of the Swiss population.

Scheduling system and cooperation

Galenica works closely with suppliers to ensure the greatest possible availability of medicines. As a result of coordinated processes, the suppliers provide information about possible supply bottlenecks at an early stage. An IT-based scheduling system helps Galenica optimise its procurement and logistics processes.

Responding to critical bottlenecks in good time

The logistics companies of the Galenica Group review the inventory range in the pharmaceutical sector on a daily basis, enabling them to respond in good time to bottlenecks and increased demand. If critical bottlenecks occur or there is an increased demand for specific products, as has been the case time and again due to COVID-19, logistics companies quickly change the way they work. The delivery of non-essential products, such as cosmetics or perfumes, is temporarily discontinued, if necessary, in order to guarantee the supply of essential products. In addition, the amount that each customer can order is reduced to prevent hoarding purchases.

Evaluation of the management approach and measures

Availability of medicines

The availability of medicines is a major global challenge and naturally also affects the Swiss market. Over the past two years, COVID-19 has clearly demonstrated how disruptions in global supply chains have a negative impact on local availability. The more important it is that drugs that are available in principle or will be available again can be delivered to service providers as quickly as possible. Here, Galenica’s logistics operations manage to make and keep over 99% of these medications available throughout Switzerland within 24 hours. In 2023, Galexis and its partner Sandoz launched the Safety Stock Initiative to increase the security of supply of medicines to the Swiss population.

Galenica uses cookies to optimise the functions of the website and to ensure you enjoy the best possible experience. Use of cookies & disclaimer